# Investigation of Efficacy and Safety of EPOGAM

> **NCT00878670** · PHASE4 · COMPLETED · sponsor: **Max Zeller Soehne AG** · enrollment: 23 (actual)

## Conditions studied

- Atopic Dermatitis
- Neurodermatitis

## Interventions

- **DRUG:** EPOGAM 1000

## Key facts

- **NCT ID:** NCT00878670
- **Lead sponsor:** Max Zeller Soehne AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878670, "Investigation of Efficacy and Safety of EPOGAM". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00878670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*